The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Validation of MRD as a surrogate endpoint in AML: ongoing research & updates from HARMONY Alliance
Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, discusses a HARMONY Alliance study showing how measurable residual disease (MRD) refines prognostic risk in acute myeloid leukemia (AML) and may serve as an early surrogate endpoint to guide treatment decisions and clinical trials. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is another activity of us at the Harmony Alliance Foundation. We are following also the other risk factors that are relevant to AML because although genetics at initial diagnosis, what we have been focusing on in my abstract, is a hallmark attributing to about 63% of the factors that are relevant for prognosis. It’s modified with other factors, including age and also other factors such as treatments...
This is another activity of us at the Harmony Alliance Foundation. We are following also the other risk factors that are relevant to AML because although genetics at initial diagnosis, what we have been focusing on in my abstract, is a hallmark attributing to about 63% of the factors that are relevant for prognosis. It’s modified with other factors, including age and also other factors such as treatments. But the MRD, so the minimal residual and measurable residual disease, are adding value and they are refining risk for those patients after the treatments because the persistence of MRD is a risk factor, an independent risk factor. More importantly, and this is what my colleague has been focusing on, this is a factor that really can be utilized as a surrogate parameter because it becomes positive earlier. And this has impacts, of course, to clinical trials because clinical trials usually wait for the signals which are mortality or relapse signals. But if you can detect them, anticipate them, you can accelerate the treatment, and you can intervene earlier when it’s better to cure patients, for example, with an allogeneic transplantation. And the surrogacy of the MRD has been investigated previously, but not in that scale, and he was able to merge data for 1,800 patients to really investigate this diverse impact of the MRD. So good updates, hopefully also for the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
